1. 264TiPENGOT-ov43/KEYLYNK-001: A phase III trial of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA¬-nonmutated advanced epithelial ovarian cancer. (24th November 2019) Authors: Fujiwara, K; Vergote, I B; Sehouli, J; Salutari, V; Zola, P; Madry, R; Wenham, R M; Korach, J; Pautier, P; Cibula, D; Lheureux, S; Hasegawa, K; Kim, B-G; Lai, C-H; Gonzalez-Martinez, A; Liu, Q; Keefe, S M; Puglisi, M; Topuz, S Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 323 ENGOT-en9/LEAP-001: a phase 3 study of first-line pembrolizumab plus lenvatinib compared with chemotherapy in advanced or recurrent endometrial cancer. (13th November 2020) Authors: Randall, L; Marth, C; Vulsteke, C; Jesús Rubio, M; Makker, V; Braicu, I; McNeish, I; Madry, R; Ayhan, A; Hasegawa, K; Wu, X; Dutta, L; Xu, C; Keefe, S; Lee, J; Pignata, S Journal: International journal of gynecological cancer Issue: Volume 30(2020)Supplement 3 Page Start: A130 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial. (18th September 2019) Authors: Penson, RT; Valencia, RV; Cibula, D; Colombo, N; III, CL; Bidzinski, M; Kim, JW; Nam, JH; Madry, R; Hernández, CH; Mora, P; Ryu, SY; Milenkova, T; Lowe, e; Barker, L; Scambia, G Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. EP803 The real-world effect of olaparib in BRCA-dependent platinum-sensitive recurrent ovarian cancer patients in Poland. (1st November 2019) Authors: Blecharz, P; Madry, R Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P154 Tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase 3 INNOVATE/ENGOT-ov50 study. (1st November 2019) Authors: Vergote, I; Copeland, L; Monk, B; Coleman, R; Cibula, D; Sehouli, J; Samartzis, EP; Madry, R; González Martin, A; Korach, J; Salutari, V; Witteveen, PO; O'Malley, D Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 4 Page Start: A152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety and dose modification for patients receiving niraparib. (13th August 2018) Authors: Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W Journal: Annals of oncology Issue: Volume 30:Number 5(2019) Page Start: 859 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and dose modification for patients receiving niraparib. (14th May 2018) Authors: Berek, J S; Matulonis, U A; Peen, U; Ghatage, P; Mahner, S; Redondo, A; Lesoin, A; Colombo, N; Vergote, I; Rosengarten, O; Ledermann, J; Pineda, M; Ellard, S; Sehouli, J; Gonzalez-Martin, A; Berton-Rigaud, D; Madry, R; Reinthaller, A; Hazard, S; Guo, W Journal: Annals of oncology Issue: Volume 29:Number 8(2018) Page Start: 1784 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗